Cencora, Inc. $COR Shares Sold by Black Creek Investment Management Inc.

Black Creek Investment Management Inc. trimmed its holdings in shares of Cencora, Inc. (NYSE:COR) by 26.9% in the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 37,140 shares of the company’s stock after selling 13,673 shares during the period. Cencora comprises approximately 0.5% of Black Creek Investment Management Inc.’s holdings, making the stock its 19th biggest holding. Black Creek Investment Management Inc.’s holdings in Cencora were worth $11,136,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also recently bought and sold shares of COR. Bailard Inc. purchased a new stake in shares of Cencora in the first quarter valued at $219,000. Kingsview Wealth Management LLC increased its position in Cencora by 21.1% during the 1st quarter. Kingsview Wealth Management LLC now owns 2,620 shares of the company’s stock worth $728,000 after purchasing an additional 457 shares in the last quarter. Private Advisor Group LLC raised its stake in Cencora by 9.2% in the 1st quarter. Private Advisor Group LLC now owns 6,796 shares of the company’s stock valued at $1,890,000 after purchasing an additional 572 shares during the last quarter. Kestra Private Wealth Services LLC lifted its holdings in Cencora by 10.9% in the 1st quarter. Kestra Private Wealth Services LLC now owns 10,750 shares of the company’s stock valued at $2,989,000 after purchasing an additional 1,058 shares in the last quarter. Finally, J.W. Cole Advisors Inc. boosted its stake in shares of Cencora by 49.3% during the 1st quarter. J.W. Cole Advisors Inc. now owns 6,018 shares of the company’s stock worth $1,674,000 after purchasing an additional 1,987 shares during the last quarter. Hedge funds and other institutional investors own 97.52% of the company’s stock.

Insider Activity at Cencora

In related news, CEO Robert P. Mauch sold 5,097 shares of the company’s stock in a transaction on Monday, October 20th. The shares were sold at an average price of $326.80, for a total transaction of $1,665,699.60. Following the completion of the sale, the chief executive officer directly owned 37,940 shares of the company’s stock, valued at approximately $12,398,792. This represents a 11.84% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Chairman Steven H. Collis sold 31,350 shares of the stock in a transaction on Tuesday, September 16th. The shares were sold at an average price of $289.86, for a total value of $9,087,111.00. Following the completion of the sale, the chairman owned 305,913 shares of the company’s stock, valued at approximately $88,671,942.18. This represents a 9.30% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Over the last quarter, insiders have sold 41,544 shares of company stock valued at $12,230,941. 10.80% of the stock is owned by insiders.

Cencora Price Performance

Shares of Cencora stock opened at $365.22 on Tuesday. The business’s fifty day moving average price is $322.71 and its 200 day moving average price is $302.76. Cencora, Inc. has a twelve month low of $223.92 and a twelve month high of $369.00. The company has a current ratio of 0.90, a quick ratio of 0.53 and a debt-to-equity ratio of 3.64. The stock has a market capitalization of $70.81 billion, a P/E ratio of 37.57, a PEG ratio of 1.56 and a beta of 0.63.

Cencora (NYSE:COR) last released its quarterly earnings data on Wednesday, November 5th. The company reported $3.84 EPS for the quarter, topping analysts’ consensus estimates of $3.79 by $0.05. The company had revenue of $83.73 billion for the quarter, compared to the consensus estimate of $83.36 billion. Cencora had a return on equity of 267.36% and a net margin of 0.60%.The company’s quarterly revenue was up 5.9% compared to the same quarter last year. During the same period last year, the business posted $3.34 EPS. Cencora has set its FY 2026 guidance at 17.450-17.75 EPS. As a group, research analysts anticipate that Cencora, Inc. will post 15.37 earnings per share for the current year.

Cencora Increases Dividend

The firm also recently declared a quarterly dividend, which will be paid on Monday, December 1st. Shareholders of record on Friday, November 14th will be given a dividend of $0.60 per share. This represents a $2.40 dividend on an annualized basis and a yield of 0.7%. This is a positive change from Cencora’s previous quarterly dividend of $0.55. The ex-dividend date of this dividend is Friday, November 14th. Cencora’s dividend payout ratio is presently 30.19%.

Analyst Ratings Changes

A number of equities analysts have recently weighed in on the stock. UBS Group upped their price objective on shares of Cencora from $380.00 to $415.00 and gave the company a “buy” rating in a research note on Friday, November 7th. TD Cowen boosted their price target on Cencora from $350.00 to $400.00 and gave the company a “buy” rating in a report on Monday, November 10th. JPMorgan Chase & Co. raised their price objective on Cencora from $344.00 to $417.00 and gave the stock an “overweight” rating in a report on Tuesday, November 11th. Wells Fargo & Company lifted their price objective on Cencora from $354.00 to $405.00 and gave the company an “overweight” rating in a research report on Tuesday, November 11th. Finally, Evercore ISI set a $400.00 target price on Cencora and gave the stock an “outperform” rating in a research report on Thursday, November 6th. Nine analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the company. According to data from MarketBeat, Cencora currently has a consensus rating of “Moderate Buy” and an average target price of $371.09.

Cencora Company Profile

Cencora, Inc sources and distributes pharmaceutical products. The company's U.S. Healthcare Solutions segment distributes pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to various institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and additional services for biotechnology and pharmaceutical manufacturers; pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets; and sales force services to manufacturers.